Movement disorders


Senior physician

Ubaldo Del Carro


The Movement Disorders Unit is focused on understanding the physiopathological mechanisms responsible for different movement disorders, arising from both central and peripheral nervous system dysfunctions. We are involved in the clinical and neurophysiological validation studies on safety and efficacy of innovative therapeutic strategies, both in clinical practice and in experimental settings.

We are studying several animal models of human acquired and inherited diseases in order to characterize underlying physiopathological mechanism and to provide a sensitive model to verify the response to experimental therapies. Further, we are committed in the translation process of these new therapeutic approach in human pathology, like the deep brain stimulation in several basal ganglia disorders or lentiviral hematopoietic stem cell gene therapy in metachromatic leukodystrophy.

Research activity

Notably we are studying the functional recovery after botulinum toxin type A (BT-A) therapy in patients with focal spasticity in multiple sclerosis (MS), the tuning of the treatment of neurogenic bladder by BT-A injection into the detrusor muscle, as well as the cortical excitability modifications in dystonic diseases. We are studing the transcranial magnetic stimulation (TMS) effect on the exteroceptive suppression (“geste antagoniste”) in cervical dystonia (CD). We are also keeping on our animal neurophysiological studies in several models of experimental peripheral neuropathy, like the nervous regeneration after crush. However, neurophysiological measurements of nerve regeneration still need a gold standard method. We are exploring whether the association of classical neurophysiological tests and stimulated single fiber electromyography (SFEMG) may contribute to better describe axonal fibers regeneration in experimental models.